Mablink announces the publication of a review article titled “Payload diversification: a key step in the development of antibody–drug conjugates”. Its authors Louise Conilh, Lenka Kyrych Sadilkova, Warren Viricel and …
The financing will enable the company to advance its lead candidate to the clinic and to build a pipeline of next-generation antibody-drug conjugates (ADCs) Its proprietary ADC technology opens the …
Mablink Bioscience appoints Dr. Lenka Kyrych Sadilkova as its Head of Preclinical Research and Development to support the development of its pipeline of ADC candidates using its proprietary PSARlink™ linker …
Mablink Bioscience appoints its Chief Development Officer to support the regulatory development of its lead candidate MBK-103, an ADC using its proprietary PSARlink™ linker Lyon, France, March 1, 2022 Mablink …
Emergence Therapeutics obtains the rights to develop a novel antibody-drug conjugate using Mablink Bioscience’s proprietary PSARlink™ drug-linker technology Lyon, France & Duisburg, Germany, October 21, 2021 Mablink Bioscience S.A.S. a …
Edouard LEROY Chief Business Officer of Mablink, participates (digitally) in the next edition of the event BIO-Europe, held as a digital event from October 25 to 28, 2021. BIO-Europe is …
Dans un article paru le vendredi 30 septembre 2021, dans le cadre de sa série “Les biotechs à suivre”, le quotidien La Tribune fait le portrait de Mablink Bioscience, des …
Mablink Bioscience to move forward its ADC pipeline targeted at cancers with high unmet medical needs Lyon, France, April 27, 2021 Mablink Bioscience, a company developing the next generation of …
Mablink’s R&D team authored a scientific article published today (March 9) in the journal “Pharmaceuticals”. The paper “Exatecan Antibody Drug Conjugates based on a hydrophilic polysarcosine Drug-Linker platform” characterizes a …
Le quotidien “Le Figaro” s’est fait l’écho de l’engouement de l’industrie pharmaceutique pour l’approche ADC (anticorps conjugués) dans un article publié le 3 mars : lien vers l’article. Mablink est …
